Zirconium cyclosilicate for treatment of hyperkalemia

JAMA - Journal of the American Medical Association

Volumn 312, Issue 21, 2014, Pages 2217-2218

  Bradley S, Dixon ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; SILICATE; ZIRCONIUM;

CELL DAMAGE; CELL MEMBRANE POTENTIAL; CLINICAL FEATURE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EXTRACELLULAR SPACE; HUMAN; HYPERKALEMIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; FEMALE; MALE;

FEMALE; HUMANS; HYPERKALEMIA; MALE; POTASSIUM; SILICATES; ZIRCONIUM;

EID: 84914673764     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.15736     Document Type: Editorial

References (17)

1. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30(3):e156-e166.
2. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109(10):1510-1513.
3. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases. Br J Pharmacol. 2010;160(6):1273-1292.
4. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592.
5. Gheorghiade M, Albert NM, Curtis AB, et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention. Congest Heart Fail. 2012;18(1):9-17.
6. Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77(914):759-764.
7. Alfonzo AV, Isles C, Geddes C, Deighan C. Potassium disorders. Resuscitation. 2006;70(1):10-25.
8. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324-330.
9. Kamel KS, Schreiber M, Halperin ML. Integration of the response to a dietary potassium load. Nephrol Dial Transplant. 2014;29(5):982-989.
10. Welling PA. Regulation of renal potassium secretion. Semin Nephrol. 2013;33(3):215-228.
11. Bakris GL, Siomos M, Richardson D, et al; VAL-K Study Group. ACE inhibition or angiotensin receptor blockade. Kidney Int. 2000;58(5):2084-2092.
12. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia. J Am Soc Nephrol. 2010;21(5):733-735.
13. McCullough PA, Beaver TM, Bennett-Guerrero E, et al. Acute and chronic cardiovascular effects of hyperkalemia. Rev Cardiovasc Med. 2014;15(1):11-23.
14. Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen H. Safety and efficacy of ZS-9, a novel selective cation trap, for treatment of hyperkalemia in CKD patients [abstract]. J Am Soc Nephrol. 2013;24:2B.
15. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA. doi:10.1001/jama.2014.15688.
16. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease. BMJ. 2013;346:f1378.
17. Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 2010;56(2):338-347.